Home / Business and Economy / GE HealthCare Buys SOFIE Biosciences for $945M
GE HealthCare Buys SOFIE Biosciences for $945M
5 Oct
Summary
- GE HealthCare to acquire SOFIE Biosciences for $945 million cash.
- SOFIE operates 15 U.S. manufacturing sites for PET radiopharmaceuticals.
- Acquisition expected to enhance GEHC's role in radiopharmaceutical supply.
GE HealthCare announced on October 5, 2026, a definitive agreement to acquire SOFIE Biosciences for $945 million in cash. SOFIE Biosciences, a U.S.-based contract manufacturing organization (CMO) for PET radiopharmaceuticals, operates 15 sites across the U.S.
The acquisition is set to close in the first half of 2027, subject to regulatory approvals. This strategic move establishes GE HealthCare's presence in the 'final mile' of U.S. PET radiopharmaceutical supply, enabling participation in high-growth areas and enhancing patient access to novel treatments.
SOFIE Biosciences' network includes 15 CMO sites with 21 cyclotrons and a theranostics-focused CDMO site. The integration is expected to be accretive to GE HealthCare's revenue growth and earnings per share in its first full year of ownership.
GE HealthCare aims to leverage its global scale to invest in and grow SOFIE Biosciences, improving supply reliability and supporting next-generation precision care products. The deal also allows GE HealthCare to advance its pipeline of radiopharmaceutical products, including its FAPI-74 asset for oncologic and non-oncologic indications.
